Danish Child Cancer Foundation Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2005
NCT00192673
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Danish Child Cancer Foundation

Active Ingredients

Drugs in Phase 4 Trials (1)

pegaspargase (oncaspar) (1 trial)

Drugs in Phase 2 Trials (1)

tioguanine (Lanvis) (1 trial)

Drugs in Other Trials (2)

canola oil (1 trial)

fish oil (Omegavan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4